Hydromer Announces Launch of HydroThrombX Medical Device Coating Technology

CONCORD, NC -- June 5, 2024 -- InvestorsHub NewsWire -- Hydromer, Inc. (OTC: HYDI) (the "Company"), a leader in hydrophilic, thromboresistant, and antimicrobial coating technologies for medical devices for over 44 years, is pleased to announce the launch of HydroThrombX ™, a next generation version of the Company's current legacy product F200t, a thromboresistant coating well-known in the industry for significantly reducing platelet adhesion and cell mitosis, aiding in the prevention of restenosis.

HydroThrombX product is currently available and being marketed to current and new customers. The product was created to be compliant with the REACH (Registration, Evaluation, Authorization, and Restriction of Chemicals) and CE organizations, meeting the European Union's (EU) strict safety, health, and environmental protection standards.

Mike Torti, Hydromer's CEO, shared: "We're thrilled to release our new and improved, NMP-free anti-thrombogenic coating, which ensures greater safety and environmental sustainability. Fully compliant with the latest regulations while still maintaining its efficacy."

Any medical device inserted into the body has the potential to cause blood clots which can lead to thrombosis or an embolism. When a medical device coating is thromboresistant, it reduces the risk of blood clot formation which can lead to atrial fibrillation, strokes, or even heart attacks. This is an indispensable attribute in a coating for medical devices such as catheters and vascular implants.

By reducing the adherence of blood to the surface of a medical device, management believes the HydroThrombX technology could improve patient safety and clinical outcomes, while also extending the life of the device.

About Hydromer

Hydromer, Inc. is an ISO 9001:2015 global business-to-business (B2B) surface modification and coating solutions provider offering polymer R&D and manufacturing services capabilities for a wide variety of applications. We are domiciled in Concord, NC. Our customers are located across the United States, Europe and Asia-Pacific. Our facilities are U.S. Food and Drug Administration (FDA), Good Manufacturing Practice (GMP), International Organization for Standardization (ISO) 13485, and International Organization for Standardization (ISO) 9001 compliant. For over four decades, the Company has developed value-added solutions to serve businesses in domestic and international markets in a wide range of industries. We manage numerous global B2B services such as coating services, research and development, analytical testing, technology transfer, and dedicated machinery building, installation, and support. We have successfully developed numerous proprietary formulations and hold many patents worldwide, including those with anti-microbial, anti-fog, anti-frost, condensation-controlling, hydrophilic, and thromboresistant coating applications.

Contact: Hydromer Inc.

Info@hydromer.com

800-326-5976

Forward-Looking Statements

This press release contains forward-looking statements that are based on Hydromer's current expectations, estimates, forecasts, and projections. These statements are not guarantees of future performance and involve risks, uncertainties, assumptions, and other factors that are difficult to predict and could cause actual results to differ materially from those expressed or anticipated. We caution readers not to place undue reliance on these forward-looking statements. Hydromer undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.

Hydromer (CE) (USOTC:HYDI)
過去株価チャート
から 11 2024 まで 12 2024